No insider purchase over the last 90 days. The latest, by 차미영, was filed 29 May 2026.
Who traded when
BuySale+6 other insiders
Since the insiders bought
- -52.2%Entry ₩7,340 · Close 30 Oct 2026 ₩3,505
- -23.1%Entry ₩3,660 · Close at T+365 ₩2,815
- -23.1%Entry ₩3,660 · Close at T+365 ₩2,815
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- 20,000 sharesShareKRXDART:20260529002242
- 18,450 sharesKRXDART:20260529002234
- 20,000 sharesShareKRXDART:20260529002262Canonical exit: 19 Aug 2026 (T+90)
- 500,000 sharesKRXDART:20260527000533
- 1,456,193 sharesKRXDART:20260527000552
- 26,000 shares@ ₩3,040.000.049% mcap45.6% of flowShareKRXDART:20260430001371Canonical exit: 22 Jul 2026 (T+90)
- 6,000 shares@ ₩10,000.000.037% mcap100.0% of flowShareKRXDART:20260330001321
- 10,000 shares@ ₩9,455.000.058% mcap54.4% of flowShareKRXDART:20260330001302
- ●Executives0DART
- 165,385 sharesKRXDART:20260130000610
- 1,517,190 sharesKRXDART:20260105000339Canonical exit: 29 Mar 2026 (T+90)
- 819,112 sharesKRXDART:20251218000468
- ●Executives0DART
- 1,613,125 sharesKRXDART:20250808000628Canonical exit: 9 Oct 2025 (T+90)
- ●Executives0DART
- 90,000 sharesKRXDART:20250509000792
- 100,000 sharesShareKRXDART:20250509000779
- 40,000 sharesShareKRXDART:20250509000818Canonical exit: 7 Aug 2025 (T+90)
- 90,000 sharesShareKRXDART:20250509000807
- 100,000 sharesKRXDART:20250509000776
- 50,000 sharesShareKRXDART:20250509000822Canonical exit: 7 Aug 2025 (T+90)
- 20,000 sharesShareKRXDART:20250509000845Canonical exit: 7 Aug 2025 (T+90)
- 10,000 sharesShareKRXDART:20250509000842Canonical exit: 7 Aug 2025 (T+90)
25 of 80 declarations
About Genome & Company
지놈앤컴퍼니 (Genome & Company) has 78 filings, but two filers dominate, both classed as 대량보유자: 배지수 with 34 filings (2 purchases, 2 sales) and 박한수 with 22 (2 purchases, 6 sales). This South Korean health care company, listed on the Korea Exchange, is worth KRW 190.4 billion, and insiders hold 14.7% of the capital.
Open-market trades split almost evenly: 17 purchases for 16 sales, or 52% purchases. Amounts are modest. The only purchase with an amount, EUR 45,606, is 서진경's (상무) on April 23, 2026. Two sales carry an amount, EUR 54,461 for 서진경 on March 26, 2026 and EUR 34,440 for 유현경 (상무) on March 27, 2026, or EUR 88,901 in all.
Read moreShow less
Between April 28 and May 9, 2025, 7 filers bought. Filings, published between March 26, 2021 and May 29, 2026, are spread fairly evenly, from 9 in 2022 to 16 in 2025. Over the last twelve months there are 13 filings, of which 3 purchases and 8 sales. On the 46 filings where the delay is known, a typical filing is published 7 days after the trade.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
